Preclinical and Clinical Investigations in Septic Shock

感染性休克的临床前和临床研究

• 批准号: 7215797
• 负责人: ROBERT L DANNER
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7215797
• 关键词: antiinflammatory agents; aortic balloon pump; biomarker; dogs; drug screening /evaluation; endotoxins; epinephrine; glucocorticoids; human subject; human therapy evaluation; hypothalamic pituitary adrenal axis; ibuprofen; nitric oxide; norepinephrine; passive immunization; pathologic process; patient oriented research; pneumonia; respirators; septic shock; vasodilation; vasopressins

Introduction and Objective: Septic shock is a highly lethal syndrome initiated by severe, overwhelming infection. This condition is the leading cause of death in Intensive Care Units in the U.S. The underlying mechanisms that cause this syndrome remain incompletely understood despite more than a half century of scientific investigation. These studies seek to examine septic shock pathogenesis and to explore the potential of novel therapeutic strategies using both small and large models of the syndrome, patients with sepsis, and normal volunteers challenged with endotoxin. Proposed Course of Work: Ongoing comparative survival study of commonly used vasopressors in septic shock including epinephrine, norepinephrine and vasopressin. Protocols under development for lymphocyte adoptive transfer, and intra-aortic balloon pump support in septic shock. Investigate the hypothalmic-pituitary-adrenal axis in sepsis and the mechanisms by which low dose glucocorticoid replacement therapy improves survival in septic shock. Validate and apply information on biomarkers and pathogenic pathways obtained from functional genomic investigations.

引言和目标：败血性休克是一种高度致命的综合征，由严重的压倒性感染引发。这种情况是美国重症监护病房中死亡的主要原因，尽管有超过半个世纪的科学研究，导致该综合征的基本机制仍未完全理解。 这些研究试图检查败血性休克发病机理，并使用综合征的小型和大型综合征，败血症患者和正常志愿者对内毒素提出质疑的新型治疗策略的潜力。 建议的工作课程： 败血性休克中常用加压剂的持续比较生存研究，包括肾上腺素，去甲肾上腺素和加压素。 淋巴细胞收养转移的开发方案和化粪池休克中的 - 运动气球内泵支持。 研究败血症中的下型 - 垂体 - 肾上腺轴，以及低剂量的糖皮质激素替代疗法可提高败血性休克中的生存率。 验证并应用有关从功能基因组研究获得的生物标志物和致病途径的信息。